{"id":65040,"date":"2026-05-12T14:32:36","date_gmt":"2026-05-12T06:32:36","guid":{"rendered":"https:\/\/flcube.com\/?p=65040"},"modified":"2026-05-12T14:32:36","modified_gmt":"2026-05-12T06:32:36","slug":"tortugas-neuroscience-raises-106m-in-seed-and-series-a-financing-to-advance-cns-pipeline-from-eisai-and-hansoh","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65040","title":{"rendered":"Tortugas Neuroscience Raises $106M in Seed and Series A Financing to Advance CNS Pipeline from Eisai and Hansoh"},"content":{"rendered":"\n<p><strong>Tortugas Neuroscience<\/strong>, a clinical-stage biotechnology company focused on central nervous system (CNS) disorders, announced the successful completion of <strong>seed and Series A financing rounds<\/strong>, raising <strong>$106 million<\/strong> in total capital. The proceeds will fund ongoing research and development programs, including <strong>Phase II clinical studies<\/strong> for two core drug candidates in-licensed from <strong>Eisai Co., Ltd.<\/strong> (Tokyo) and <strong>Hansoh Pharmaceutical Group Ltd.<\/strong> (Greater China).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financing-details\">Financing Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Tortugas Neuroscience (US-based)<\/td><\/tr><tr><td><strong>Total Raised<\/strong><\/td><td>USD 106 million<\/td><\/tr><tr><td><strong>Financing Rounds<\/strong><\/td><td>Seed + Series A (concurrent\/completed)<\/td><\/tr><tr><td><strong>Seed Lead<\/strong><\/td><td>Cure Ventures (founding investor)<\/td><\/tr><tr><td><strong>Series A Co-Leads<\/strong><\/td><td>Cure Ventures, The Column Group, AN Venture Partners<\/td><\/tr><tr><td><strong>Use of Proceeds<\/strong><\/td><td>Phase II clinical studies + R&amp;D programs for CNS pipeline<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pipeline-portfolio-amp-strategic-assets\">Pipeline Portfolio &amp; Strategic Assets<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Therapeutic Focus:<\/strong> High unmet need CNS indications including schizophrenia, tinnitus, focal epilepsy, and reversible encephalopathy<\/li>\n\n\n\n<li><strong>Licensing Strategy:<\/strong> In-licensed clinical-stage assets from established pharmaceutical partners<\/li>\n\n\n\n<li><strong>Hansoh-Derived Assets:<\/strong><\/li>\n\n\n\n<li><strong>TRTL-107\/HS-10380<\/strong>: Schizophrenia candidate<\/li>\n\n\n\n<li><strong>TRTL-913\/HS-10353<\/strong>: Tinnitus candidate<\/li>\n\n\n\n<li><strong>Eisai-Derived Assets:<\/strong> Additional CNS candidates (specific compounds undisclosed)<\/li>\n\n\n\n<li><strong>Development Stage:<\/strong> Clinical-stage pipeline with Phase II-ready candidates<\/li>\n\n\n\n<li><strong>Geographic Coverage:<\/strong> Global rights (assumed) from Japanese and Chinese pharmaceutical partners<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-significance\">Strategic Significance<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>CNS Investment Climate<\/strong><\/td><td>Despite historical challenges, select investors backing differentiated CNS assets with clear path to value inflection<\/td><\/tr><tr><td><strong>Partnership Model<\/strong><\/td><td>Leverages established pharma companies&#8217; R&amp;D investments while providing them non-dilutive monetization<\/td><\/tr><tr><td><strong>Geographic Bridge<\/strong><\/td><td>Uniquely positioned with assets from both Japanese (Eisai) and Chinese (Hansoh) pharmaceutical leaders<\/td><\/tr><tr><td><strong>Investor Consortium<\/strong><\/td><td>Mix of specialized healthcare VCs (Cure Ventures), life science specialists (The Column Group), and Asia-focused investors (AN Venture Partners)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The financing validates Tortugas&#8217; strategy of acquiring promising CNS assets from major pharmaceutical companies and advancing them through critical clinical inflection points with specialized expertise.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>CNS Therapeutic Gap<\/strong> | Schizophrenia affects ~24 million globally; tinnitus impacts ~15% of population with no approved pharmacological treatments<\/li>\n\n\n\n<li><strong>Competitive Advantage<\/strong> | Access to clinically-validated compounds reduces early-stage development risk<\/li>\n\n\n\n<li><strong>Value Creation Timeline<\/strong> | Phase II data readouts expected within 18\u201324 months, creating near-term catalyst opportunities<\/li>\n\n\n\n<li><strong>Exit Potential<\/strong> | Strong strategic interest from large pharma in validated CNS assets addressing high unmet needs<\/li>\n\n\n\n<li><strong>Investment Thesis<\/strong> | Specialized CNS biotech model gaining traction as big pharma focuses on late-stage assets<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding financing activities, development timelines, clinical trial plans, and commercial expectations for Tortugas Neuroscience&#8217;s pipeline. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and capital market conditions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Tortugas Neuroscience, a clinical-stage biotechnology company focused on central nervous system (CNS) disorders, announced the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[350,363,4734],"class_list":["post-65040","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-eisai","tag-hansoh-pharmaceutical","tag-tortugas-neuroscience"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Tortugas Neuroscience Raises $106M in Seed and Series A Financing to Advance CNS Pipeline from Eisai and Hansoh - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Tortugas Neuroscience, a clinical-stage biotechnology company focused on central nervous system (CNS) disorders, announced the successful completion of seed and Series A financing rounds, raising $106 million in total capital. The proceeds will fund ongoing research and development programs, including Phase II clinical studies for two core drug candidates in-licensed from Eisai Co., Ltd. (Tokyo) and Hansoh Pharmaceutical Group Ltd. (Greater China).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65040\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tortugas Neuroscience Raises $106M in Seed and Series A Financing to Advance CNS Pipeline from Eisai and Hansoh\" \/>\n<meta property=\"og:description\" content=\"Tortugas Neuroscience, a clinical-stage biotechnology company focused on central nervous system (CNS) disorders, announced the successful completion of seed and Series A financing rounds, raising $106 million in total capital. The proceeds will fund ongoing research and development programs, including Phase II clinical studies for two core drug candidates in-licensed from Eisai Co., Ltd. (Tokyo) and Hansoh Pharmaceutical Group Ltd. (Greater China).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65040\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-12T06:32:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65040#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65040\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Tortugas Neuroscience Raises $106M in Seed and Series A Financing to Advance CNS Pipeline from Eisai and Hansoh\",\"datePublished\":\"2026-05-12T06:32:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65040\"},\"wordCount\":415,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Eisai\",\"Hansoh Pharmaceutical\",\"Tortugas Neuroscience\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65040#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65040\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65040\",\"name\":\"Tortugas Neuroscience Raises $106M in Seed and Series A Financing to Advance CNS Pipeline from Eisai and Hansoh - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-12T06:32:36+00:00\",\"description\":\"Tortugas Neuroscience, a clinical-stage biotechnology company focused on central nervous system (CNS) disorders, announced the successful completion of seed and Series A financing rounds, raising $106 million in total capital. The proceeds will fund ongoing research and development programs, including Phase II clinical studies for two core drug candidates in-licensed from Eisai Co., Ltd. (Tokyo) and Hansoh Pharmaceutical Group Ltd. (Greater China).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65040#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65040\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65040#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tortugas Neuroscience Raises $106M in Seed and Series A Financing to Advance CNS Pipeline from Eisai and Hansoh\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Tortugas Neuroscience Raises $106M in Seed and Series A Financing to Advance CNS Pipeline from Eisai and Hansoh - Insight, China&#039;s Pharmaceutical Industry","description":"Tortugas Neuroscience, a clinical-stage biotechnology company focused on central nervous system (CNS) disorders, announced the successful completion of seed and Series A financing rounds, raising $106 million in total capital. The proceeds will fund ongoing research and development programs, including Phase II clinical studies for two core drug candidates in-licensed from Eisai Co., Ltd. (Tokyo) and Hansoh Pharmaceutical Group Ltd. (Greater China).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65040","og_locale":"en_US","og_type":"article","og_title":"Tortugas Neuroscience Raises $106M in Seed and Series A Financing to Advance CNS Pipeline from Eisai and Hansoh","og_description":"Tortugas Neuroscience, a clinical-stage biotechnology company focused on central nervous system (CNS) disorders, announced the successful completion of seed and Series A financing rounds, raising $106 million in total capital. The proceeds will fund ongoing research and development programs, including Phase II clinical studies for two core drug candidates in-licensed from Eisai Co., Ltd. (Tokyo) and Hansoh Pharmaceutical Group Ltd. (Greater China).","og_url":"https:\/\/flcube.com\/?p=65040","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-12T06:32:36+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65040#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65040"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Tortugas Neuroscience Raises $106M in Seed and Series A Financing to Advance CNS Pipeline from Eisai and Hansoh","datePublished":"2026-05-12T06:32:36+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65040"},"wordCount":415,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Eisai","Hansoh Pharmaceutical","Tortugas Neuroscience"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65040#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65040","url":"https:\/\/flcube.com\/?p=65040","name":"Tortugas Neuroscience Raises $106M in Seed and Series A Financing to Advance CNS Pipeline from Eisai and Hansoh - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-12T06:32:36+00:00","description":"Tortugas Neuroscience, a clinical-stage biotechnology company focused on central nervous system (CNS) disorders, announced the successful completion of seed and Series A financing rounds, raising $106 million in total capital. The proceeds will fund ongoing research and development programs, including Phase II clinical studies for two core drug candidates in-licensed from Eisai Co., Ltd. (Tokyo) and Hansoh Pharmaceutical Group Ltd. (Greater China).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65040#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65040"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65040#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Tortugas Neuroscience Raises $106M in Seed and Series A Financing to Advance CNS Pipeline from Eisai and Hansoh"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65040","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65040"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65040\/revisions"}],"predecessor-version":[{"id":65043,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65040\/revisions\/65043"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65040"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65040"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65040"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}